Metabolite Identification Data in Drug Discovery: Data Generation and Trend Analysis

15 May 2025, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

In drug discovery, metabolite identification data is used to identify metabolic soft spots in research molecules to facilitate reduced metabolism in subsequently designed compounds. In addition, knowledge about exact metabolite structures enables the assessment of risks associated with active, reactive, or toxic metabolites. In the present work, we exemplify how metabolite identification data is generated and utilized at AstraZeneca. We share metabolite transformation scheme data derived from incubations in human hepatocytes for a set of 120 compounds. Comparison with other in-house generated metabolite identification data, both in terms of chemical space analysis and in vitro properties, is performed, including the characterization of observed metabolic pathways. For selected compounds, the correlation between in vitro and in vivo metabolite data in animal species is provided. Finally, usage of shared metabolite identification data for drug metabolism prediction using machine learning and artificial intelligence approaches is discussed.

Keywords

Metabolite identification
Drug metabolism
LC-MS
Drug discovery
Data sharing

Supplementary weblinks

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.